These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 34627706)
1. Evaluation of minocycline combined with favipiravir therapy in coronavirus disease 2019 patients: A case-series study. Itoh K; Sakamaki I; Hirota T; Iwasaki H J Infect Chemother; 2022 Jan; 28(1):124-127. PubMed ID: 34627706 [TBL] [Abstract][Full Text] [Related]
2. A Favipiravir-induced Fever in a Patient with COVID-19. Kurita T; Ishida K; Muranaka E; Sasazawa H; Mito H; Yano Y; Hase R Intern Med; 2020; 59(22):2951-2953. PubMed ID: 33191372 [TBL] [Abstract][Full Text] [Related]
3. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial. Zhao H; Zhang C; Zhu Q; Chen X; Chen G; Sun W; Xiao Z; Du W; Yao J; Li G; Ji Y; Li N; Jiang Y; Wang Y; Zeng Q; Li W; Gong B; Chang X; Zhu F; Jiang X; Li J; Wu Z; Liu Y; Peng P; Wang G Int Immunopharmacol; 2021 Aug; 97():107702. PubMed ID: 33930706 [TBL] [Abstract][Full Text] [Related]
4. Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials. Arab-Zozani M; Hassanipour S; Ghoddoosi-Nejad D BMJ Open; 2020 Jul; 10(7):e039730. PubMed ID: 32737100 [TBL] [Abstract][Full Text] [Related]
5. Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia. Mutair AA; Shamou J; Alhumaid S; Layqah L; Ahmed GY; Thoyaja K; Mohaini MA; Almahmoud S; Barry M; Khan A; Dhama K; Al-Jamea LH; Woodman A; Rabaan AA J Infect Public Health; 2022 Apr; 15(4):389-394. PubMed ID: 35299062 [TBL] [Abstract][Full Text] [Related]
6. Two cases of novel coronavirus infection (COVID-19) with transient viral elevation using semi-quantitative real-time reverse transcription PCR and symptom relapse after completion of 10 days of favipiravir treatment. Tsuboi H; Kasamatsu Y; Matsubara S; Sasao A; Kunimitsu K; Munakata N; Ito T; Tsuchido Y; Yamawaki M; Fujita N J Infect Chemother; 2021 Jul; 27(7):1072-1075. PubMed ID: 33814353 [TBL] [Abstract][Full Text] [Related]
7. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients. Fujii S; Ibe Y; Ishigo T; Inamura H; Kunimoto Y; Fujiya Y; Kuronuma K; Nakata H; Fukudo M; Takahashi S J Infect Chemother; 2021 Jul; 27(7):1051-1057. PubMed ID: 33902990 [TBL] [Abstract][Full Text] [Related]
8. Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort. Suzuki M; Imai T; Sakurai A; Komoto S; Ide T; Lim CK; Shintani A; Doi Y; Murata T J Infect Chemother; 2021 Sep; 27(9):1350-1356. PubMed ID: 34176716 [TBL] [Abstract][Full Text] [Related]
9. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19). McCullough PA Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32967849 [TBL] [Abstract][Full Text] [Related]
10. Favipiravir-induced fever in coronavirus disease 2019: A report of two cases. Takoi H; Togashi Y; Fujimori D; Kaizuka H; Otsuki S; Wada T; Takeuchi Y; Abe S Int J Infect Dis; 2020 Dec; 101():188-190. PubMed ID: 32992014 [TBL] [Abstract][Full Text] [Related]
11. The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers. Turan DB; Menteş M; Özel Y; Şerefhanoğlu K; Aydoğan B; İbil N; Güneşdoğdu F; Orucova HM; Saltürk C; Çelik H Braz J Infect Dis; 2022; 26(1):102328. PubMed ID: 35139366 [TBL] [Abstract][Full Text] [Related]
12. Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient. Tawara J; Uehara T; Sakao S; Igari H; Taniguchi T; Kasai H; Takayanagi S; Yahaba M; Shimada R; Ikusaka M Intern Med; 2021 Apr; 60(7):1115-1117. PubMed ID: 33583886 [TBL] [Abstract][Full Text] [Related]
13. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study. Almoosa Z; Saad M; Qara S; Mustafa M; Mansour A; Alshab D; Alhashem J; ALKhawajah S; Alkhalifah S; ALmarzooq M; ALzain M; Anshasi N; Ahmed G; Mutair AA J Infect Public Health; 2021 Sep; 14(9):1247-1253. PubMed ID: 34464921 [TBL] [Abstract][Full Text] [Related]
14. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases. Murohashi K; Hagiwara E; Kitayama T; Yamaya T; Higa K; Sato Y; Otoshi R; Shintani R; Okabayashi H; Ikeda S; Niwa T; Nakazawa A; Oda T; Okuda R; Sekine A; Kitamura H; Baba T; Komatsu S; Iwasawa T; Kaneko T; Ogura T Respir Investig; 2020 Nov; 58(6):430-434. PubMed ID: 32893160 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Alamer A; Alrashed AA; Alfaifi M; Alosaimi B; AlHassar F; Almutairi M; Howaidi J; Almutairi W; Mohzari Y; Sulaiman T; Al-Jedai A; Alajami HN; Alkharji F; Alsaeed A; Alali AH; Baredhwan AA; Abraham I; Almulhim AS Curr Med Res Opin; 2021 Jul; 37(7):1085-1097. PubMed ID: 33890544 [TBL] [Abstract][Full Text] [Related]
16. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition. Takahashi H; Iwasaki Y; Watanabe T; Ichinose N; Okada Y; Oiwa A; Kobayashi T; Moriya M; Oda T Int J Infect Dis; 2020 Nov; 100():283-285. PubMed ID: 32829044 [TBL] [Abstract][Full Text] [Related]